208 related articles for article (PubMed ID: 37180636)
1. Epidemiology of Nontuberculous Mycobacteria in Nanjing and
Zhang R; Luo S; Wang N; Zhang H; Wu X
Infect Drug Resist; 2023; 16():2751-2764. PubMed ID: 37180636
[TBL] [Abstract][Full Text] [Related]
2. The TetR Family Transcription Factor MAB_2299c Regulates the Expression of Two Distinct MmpS-MmpL Efflux Pumps Involved in Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
Gutiérrez AV; Richard M; Roquet-Banères F; Viljoen A; Kremer L
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332077
[No Abstract] [Full Text] [Related]
3. Antimicrobial Susceptibility Testing Using the MYCO Test System and MIC Distribution of 8 Drugs against Clinical Isolates of Nontuberculous Mycobacteria from Shanghai.
Ying R; Yang J; Wu X; Yu F; Sha W
Microbiol Spectr; 2023 Feb; 11(2):e0254922. PubMed ID: 36802218
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in
Richard M; Gutiérrez AV; Viljoen A; Rodriguez-Rincon D; Roquet-Baneres F; Blaise M; Everall I; Parkhill J; Floto RA; Kremer L
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323043
[TBL] [Abstract][Full Text] [Related]
5. Novel Mutations Associated with Clofazimine Resistance in Mycobacterium abscessus.
Chen Y; Chen J; Zhang S; Shi W; Zhang W; Zhu M; Zhang Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712660
[No Abstract] [Full Text] [Related]
6. Sudapyridine (WX-081) antibacterial activity against
Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y
mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581
[TBL] [Abstract][Full Text] [Related]
7.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
8. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
[TBL] [Abstract][Full Text] [Related]
9. Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance
Guo Y; Yang J; Wang W; Wu X; Wan B; Wang H; Sha W; Yu F
Infect Drug Resist; 2023; 16():7587-7595. PubMed ID: 38107433
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Activity and Clinical Outcomes of Clofazimine for Nontuberculous Mycobacteria Pulmonary Disease.
Kim DH; Kim BG; Kim SY; Huh HJ; Lee NY; Koh WJ; Kim H; Kwon OJ; Jhun BW
J Clin Med; 2021 Oct; 10(19):. PubMed ID: 34640599
[TBL] [Abstract][Full Text] [Related]
11. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients.
Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y
Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium,
Zheng L; Qi X; Zhang W; Wang H; Fu L; Wang B; Chen X; Chen X; Lu Y
Front Cell Infect Microbiol; 2023; 13():1115530. PubMed ID: 37077530
[TBL] [Abstract][Full Text] [Related]
13.
Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
[TBL] [Abstract][Full Text] [Related]
14.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
15.
Zhu R; Shang Y; Chen S; Xiao H; Ren R; Wang F; Xue Y; Li L; Li Y; Chu N; Huang H
Microbiol Spectr; 2022 Dec; 10(6):e0137222. PubMed ID: 36250885
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
Zheng H; He W; Jiao W; Xia H; Sun L; Wang S; Xiao J; Ou X; Zhao Y; Shen A
BMC Infect Dis; 2021 Apr; 21(1):330. PubMed ID: 33832459
[TBL] [Abstract][Full Text] [Related]
17. Clofazimine susceptibility testing of Mycobacterium avium complex and Mycobacterium abscessus: a meta-analysis study.
Hajikhani B; Nasiri MJ; Hosseini SS; Khalili F; Karimi-Yazdi M; Hematian A; Nojookambari NY; Goudarzi M; Dadashi M; Mirsaeidi M
J Glob Antimicrob Resist; 2021 Sep; 26():188-193. PubMed ID: 34153525
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
Mougari F; Loiseau J; Veziris N; Bernard C; Bercot B; Sougakoff W; Jarlier V; Raskine L; Cambau E;
J Antimicrob Chemother; 2017 Jun; 72(6):1669-1677. PubMed ID: 28333340
[TBL] [Abstract][Full Text] [Related]
19. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
[TBL] [Abstract][Full Text] [Related]
20. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.
Ferro BE; Meletiadis J; Wattenberg M; de Jong A; van Soolingen D; Mouton JW; van Ingen J
Antimicrob Agents Chemother; 2016 Feb; 60(2):1097-105. PubMed ID: 26643335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
